US Capitol Capsule: Biopharma patent law back at Supreme Court with Copaxone
This article was originally published in Scrip
Executive Summary
The US Supreme Court is starting off its 2014-15 session with yet another patent case involving biopharmaceutical companies – this time Teva and its money-maker multiple sclerosis drug Copaxone (glatiramer acetate), whose last remaining patent was declared invalid by the US Court of Appeals for the Federal Circuit in July 2013.
You may also be interested in...
US Subpoena For Sun Amid Pricing Heat
US lawmakers continue to scrutinize drug firms amid ongoing concerns over price-related issues and their impact on healthcare costs. The US Justice Department’s antitrust division has subpoenaed Sun Pharma for information pertaining to generic drugs, pricing and certain company records, though the Indian firm claimed the move would have no immediate impact on its earnings.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.